DENV1 Specific Neutra™ Antibody Products

Are you grappling with the challenges of dengue virus research, such as viral serotype-specific neutralization, complex assay development, or the need for highly specific tools for therapeutic and vaccine evaluation? Creative Biolabs' DENV1 Specific Neutra™ Antibody Products empower your research with meticulously validated, high-affinity neutralizing antibodies, engineered through advanced recombinant technology and stringent functional screening to deliver precise and reliable results.

Introduction to Dengue Virus Type 1 (DENV1)

Dengue virus type 1 (DENV1) is a prominent member of the Flaviviridae family and one of four distinct serotypes (DENV1-4) responsible for a substantial global health burden. As an enveloped virus, it possesses a positive-sense, single-stranded RNA (ssRNA) genome. This genetic material encodes a polyprotein that is cleaved into three structural proteins, capsid (C), precursor membrane/membrane (prM/M), and envelope (E), and seven non-structural proteins essential for viral replication and host modulation.

• Structural Insights
  The mature DENV1 virion is characterized by a sophisticated icosahedral symmetry, presenting a "smooth" proteinaceous outer shell.
  • The E Protein: The surface is defined by 180 copies of the E protein, organized as 90 head-to-tail homodimers.
  • Domain Organization: The E protein is divided into three distinct domains (EDI, EDII, and EDIII).
  • Functional Significance: The E protein serves as the primary machinery for host cell receptor binding and subsequent pH-dependent membrane fusion within the endosome. Notably, Domain III (EDIII) contains the most critical serotype-specific epitopes required for potent neutralization.
• Resistance and Signaling Pathways
  DENV1 infection triggers an intricate interplay between viral replication and the host innate immune response.
  • Immune Sensing: Upon entry, viral RNA is recognized by pattern recognition receptors, specifically the RIG-I/MDA5 pathways, initiating a Type I interferon (IFN) response.
  • Inflammatory Cascades: The virus activates the NF-κB signaling pathway, contributing to the production of pro-inflammatory cytokines.
  • Immune Evasion: Pathogenesis is often exacerbated by the virus's ability to modulate or evade these signaling checkpoints, allowing for high viremia and systemic spread.

Fig.1 DENV strategies for evading innate immune responses.¹

• Clinical Impact

Infection with DENV1 results in a broad clinical spectrum, ranging from mild to life-threatening conditions: Dengue Fever (DF): A self-limiting febrile illness. Severe Dengue: Includes Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS), characterized by vascular leakage, thrombocytopenia, and organ impairment.

• Antibodies Against DENV1

The Envelope (E) protein is the immunodominant target for the development of therapeutic and diagnostic antibodies.

Neutralization Mechanisms: Potent neutralizing antibodies typically target conformational epitopes on the E protein surface. By binding to these sites, antibodies can sterically hinder receptor attachment or prevent the structural rearrangements necessary for membrane fusion.

Serotype Specificity: Antibodies directed at EDIII are particularly valued for their high degree of serotype specificity. These are indispensable tools for precise serotyping and differentiating DENV1 from other flaviviruses.

Applications of Anti-DENV1 Neutralizing Antibodies

Fig.2 Mechanism of anti-DENV1 neutralized antibody-mediated neutralization of DENV1 in cell lines.²

• Vaccine Efficacy and Immunogenicity Assessment

Anti-DENV1 neutralizing antibodies are indispensable tools for evaluating vaccine candidates. They are used in standardized plaque reduction neutralization tests (PRNT) and microneutralization assays to quantify the titer and potency of vaccine-elicited immune responses. This precise measurement is critical for determining serotype-specific protection, understanding immune correlates, and guiding vaccine development and licensure.

• Therapeutic Candidate Screening and Mechanism Study

These antibodies serve as positive controls and critical reagents in high-throughput screens for identifying novel antiviral compounds or therapeutic monoclonal antibodies. By studying how lead candidates compete with known neutralizing antibodies for E protein binding, researchers can elucidate mechanisms of action, map epitopes, and predict potential resistance, streamlining the therapeutic development pipeline.

• Advanced Diagnostic and Serological Assay Development

Highly specific anti-DENV1 antibodies enable the development of sensitive and specific diagnostic assays, such as antigen-capture ELISA for early detection of DENV1 NS1 protein. Furthermore, they are vital for serological assays that distinguish DENV1 infections from other flavivirus exposures, aiding in accurate surveillance, outbreak investigation, and patient management.

Our Anti-DENV1 Neutralizing Antibodies

Creative Biolabs delivers premium antibody solutions designed for critical dengue research:

• High Specificity and Potency: Our antibodies are rigorously validated for exclusive reactivity with DENV1, showing minimal cross-reactivity with other DENV serotypes or related flaviviruses, and exhibit high neutralization potency in functional assays.
• Diverse Epitope Coverage: We offer a portfolio targeting key neutralizing epitopes, including those on E protein domains II and III, facilitating comprehensive mechanistic and vaccine studies.
• Stringent Validation: Every batch undergoes comprehensive quality control, including SDS-PAGE, Western Blot, ELISA, and functional neutralization assays, ensuring consistent performance and reproducibility.
• Application-Optimized Formats: Available in various formats and conjugates, optimized for applications including neutralization assays, immunofluorescence, Western blotting, and ELISA.

With over two decades of expertise in antibody development and virology, Creative Biolabs is your trusted partner in infectious disease research. We combine deep scientific knowledge with cutting-edge protein engineering to provide robust, reliable tools that accelerate your project from discovery to development. Our commitment to quality, validation, and scientific support ensures you have the precise reagents needed to achieve definitive results. Contact our scientific team today to learn more and discuss how our Anti-DENV1 Specific Neutra™ Antibody Products can advance your research.

References

1. Lee, Michelle Felicia, et al. "Innate and adaptive immune evasion by dengue virus." Frontiers in cellular and infection microbiology 12 (2022): 1004608. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3389/fcimb.2022.1004608
2. Hattakam, Sararat, et al. "Repeated exposure to dengue virus elicits robust cross neutralizing antibodies against Zika virus in residents of Northeastern Thailand." Scientific Reports 11.1 (2021): 9634. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3389/fcimb.2022.1004608